PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery

Exclusion Criteria

• •Pathological diagnosis of hepatocellular carcinoma, mixed liver cancer, hilar bile duct cancer;
• •No anti-tumor treatment for Intrahepatic Cholangiocarcinoma, including chemotherapy and topical treatment, before surgery;
• •Known history of hypersensitivity to macromolecular protein preparation or any components of the SHR- 1210 formulation;
• •Tumors are not completely removed, or postoperative pathology suggests non-Intrahepatic Cholangiocarcinoma or other malignant components;
• •Subjects with any active autoimmune disease or history of autoimmune disease;
• •Uncontrolled clinically significant heart disease, including but not limited to the following: (1) \> NYHA II congestive heart failure; (2) unstable angina, (3) myocardial infarction within the past 1 year; (4) clinically significant supraventricular arrhythmia or ventricular arrhythmia requirement for treatment or intervention;
• •Active infection or an unexplained fever \> 38.5°C during screening or before the first scheduled day of dosing (subjects with tumor fever may be enrolled at the discretion of the investigator);
• •Received a live vaccine within 4 weeks of the first dose of study medication;
• •.Pregnancy or breast feeding;
• •Decision of unsuitableness by principal investigator or physician-in- charge.